ARA-290 (Cibinetide): What Researchers Are Learning

ARA-290 (Cibinetide): What Researchers Are Learning About This Tissue-Protective Peptide

Choice Peptide Labs | Research Education | June 2026

Meta description: ARA-290 (cibinetide) is an 11-amino acid peptide derived from erythropoietin that activates the innate repair receptor. Here’s what the research shows.

Introduction

What if a single peptide could capture the tissue-protective benefits of erythropoietin — without any of the risks tied to red blood cell stimulation?

That’s the question Dr. Michael Brines set out to answer in the mid-2000s. His research at Araim Pharmaceuticals led to the development of ARA-290, a synthetic 11-amino acid peptide derived from a specific region of erythropoietin (EPO) called the helix B surface. The official pharmacological name is cibinetide, though most researchers still refer to it by its developmental code.

ARA-290 works through a receptor mechanism that’s different from classical EPO signaling. Instead of stimulating red blood cell production, it activates what scientists call the innate repair receptor — a receptor complex that only appears on tissue under stress. The result is targeted anti-inflammatory and tissue-protective signaling, without the hematological side effects that limit EPO’s clinical use.

This article breaks down how ARA-290 works, what clinical trials have found so far, and why researchers are paying close attention to this compound. All information is presented for research and educational purposes only.

How ARA-290 Works: The Innate Repair Receptor

To understand ARA-290, it helps to understand its parent molecule. EPO is best known for stimulating red blood cell production — a process called erythropoiesis. But EPO has a second, lesser-known function: it protects tissue from injury through a separate signaling pathway.

ARA-290 was engineered to bind only to the innate repair receptor (IRR) — a heteromeric complex made up of the classical EPO receptor and the common beta receptor (βcR, also known as CD131). This receptor complex is distinctive because it’s only expressed on tissue that is injured, stressed, or inflamed.

When ARA-290 activates the IRR, several things happen at the cellular level:

• Anti-inflammatory signaling ramps up. Pro-inflammatory cytokines — including TNF-alpha, IL-6, and IL-1β — are reduced at the site of tissue injury.
• Cell survival pathways activate. Anti-apoptotic signaling through the PI3K/Akt and MAPK pathways helps stressed cells stay alive.
• Macrophages shift phenotype. Macrophage populations move from a pro-inflammatory M1 state toward a pro-repair M2 state.
• Nerve regeneration is supported. Axonal repair and remyelination in peripheral nerves — particularly small fiber nerves — appear to benefit.
• Microcirculation improves. Modest angiogenesis support at injury sites helps tissues receive more oxygen and nutrients during repair.

What the Research Shows

Diabetic Peripheral Neuropathy

Phase 2 trials have shown clinically meaningful improvements in neuropathic pain scores, peripheral sensation thresholds, and quality of life measures in participants with diabetic peripheral neuropathy. Small fiber density, measured through skin biopsy, showed partial regeneration in some participants.

Sarcoidosis-Associated Small Fiber Neuropathy

A randomized pilot study in 22 sarcoidosis participants tested intravenous ARA-290 versus placebo. The trial found significant symptom improvement on small fiber neuropathy scales with no major safety signals. A larger Phase 2b trial showed significant increases in corneal nerve fiber measures by corneal confocal microscopy.

Emerging Research Areas

• Anti-inflammatory and autoimmune applications — macrophage reprogramming mechanism has implications for rheumatoid arthritis and inflammatory bowel disease.
• Metabolic research — pancreatic beta cells express the IRR when stressed; ARA-290 has shown beta cell protection in animal models.
• Neuropsychiatric research — explored in treatment-resistant depression.
• Aging and frailty — a 2023 GeroScience study found reduced inflammation and improved proteostasis in aging models. (Source: PMC9889362)

ARA-290 Safety Profile

Across multiple Phase 2 trials, ARA-290 has been described as well tolerated with no dose-limiting toxicities. Reported side effects have been generally mild: occasional injection site reactions, uncommon mild fatigue or headache. Hematocrit elevation and thrombotic events have not been observed — a key differentiator from EPO.

How ARA-290 Compares to Other Research Peptides

The Discovery Story

In 2008, Dr. Michael Brines published research demonstrating that EPO’s two functions — red blood cell stimulation and tissue protection — could be separated at the molecular level. By isolating the helix B surface region of EPO, his team created a peptide that retained the tissue-protective signal while eliminating the erythropoietic activity entirely. The peptide was developed through Araim Pharmaceuticals and progressed through multiple Phase 2 clinical trials under the pharmacological name cibinetide.

What’s Next for ARA-290?

As of 2026, ARA-290 is not FDA approved for any indication. Multiple dose-ranging studies are registered on ClinicalTrials.gov and EU trial registers. The research community is watching questions around dose optimization, cycle timing, broader applications, and long-term durability of nerve regeneration signals.

Key Takeaways

ARA-290 (cibinetide) represents a meaningful shift in how scientists think about tissue protection and repair. By selectively activating the innate repair receptor — a receptor complex only expressed on injured tissue — it delivers targeted anti-inflammatory and neuroprotective signaling without the hematological risks associated with EPO. Phase 2 trials have shown objective nerve regeneration and meaningful symptom improvement with a notably clean safety profile.

This article is for research and educational purposes only. ARA-290 is not FDA approved and is sold as a research compound. Nothing in this article constitutes medical advice, dosing recommendations, or claims about treating, curing, or preventing any condition.

Sources:

• Brines M et al. — Phase 2 clinical trial publications on ARA-290 in neuropathy
• ClinicalTrials.gov — NCT02039687
• PubChem — Cibinetide (CID 91810664)
• PMC9889362 — GeroScience, 2023